Back to Directory
Zavegepant
Cognitive EnhancementPACAP antagonist nasal spray for acute migraine treatment, FDA-approved.
Key Benefits
- ✓Treats acute migraine
- ✓Nasal spray convenience
- ✓Rapid onset
- ✓Alternative to triptans
- ✓No cardiovascular concerns
Dosing Information
Dosage Range
10 mg
Frequency
As needed for migraine
Typical Duration
Per migraine attack
Detailed Protocol
Administered as nasal spray at onset of migraine. Can repeat dose after 2 hours if needed. Maximum 2 doses in 24 hours. Prescription required.
About Zavegepant
Zavegepant (Zavzpret) is a small-molecule PACAP receptor antagonist formulated as nasal spray for acute migraine treatment. First intranasal CGRP/PACAP pathway antagonist approved. FDA-approved in 2023.
Research Notes
FDA-approved in 2023 for acute migraine. First nasal spray in class. Clinical trials showed efficacy similar to oral gepants with convenience of nasal administration.
Potential Side Effects
- •Dysgeusia (altered taste)
- •Nasal discomfort
- •Nausea
- •Vomiting
Always consult with a healthcare professional before starting any peptide therapy.